Immunological targeting of cytomegalovirus for glioblastoma therapy.
Publication
, Journal Article
Nair, SK; Sampson, JH; Mitchell, DA
Published in: Oncoimmunology
2014
Human cytomegalovirus (CMV) is purportedly present in glioblastoma (GBM) while absent from the normal brain, making CMV antigens potentially ideal immunological anti-GBM targets. We recently demonstrated that patient-derived CMV pp65-specific T cells are capable of recognizing and killing autologous GBM tumor cells. This data supports CMV antigen-directed immunotherapies against GBM.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Oncoimmunology
DOI
ISSN
2162-4011
Publication Date
2014
Volume
3
Start / End Page
e29289
Location
United States
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3204 Immunology
- 1112 Oncology and Carcinogenesis
- 1107 Immunology
Citation
APA
Chicago
ICMJE
MLA
NLM
Nair, S. K., Sampson, J. H., & Mitchell, D. A. (2014). Immunological targeting of cytomegalovirus for glioblastoma therapy. Oncoimmunology, 3, e29289. https://doi.org/10.4161/onci.29289
Nair, Smita K., John H. Sampson, and Duane A. Mitchell. “Immunological targeting of cytomegalovirus for glioblastoma therapy.” Oncoimmunology 3 (2014): e29289. https://doi.org/10.4161/onci.29289.
Nair SK, Sampson JH, Mitchell DA. Immunological targeting of cytomegalovirus for glioblastoma therapy. Oncoimmunology. 2014;3:e29289.
Nair, Smita K., et al. “Immunological targeting of cytomegalovirus for glioblastoma therapy.” Oncoimmunology, vol. 3, 2014, p. e29289. Pubmed, doi:10.4161/onci.29289.
Nair SK, Sampson JH, Mitchell DA. Immunological targeting of cytomegalovirus for glioblastoma therapy. Oncoimmunology. 2014;3:e29289.
Published In
Oncoimmunology
DOI
ISSN
2162-4011
Publication Date
2014
Volume
3
Start / End Page
e29289
Location
United States
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 3204 Immunology
- 1112 Oncology and Carcinogenesis
- 1107 Immunology